Estimating Global Epidemiology of Low-Pathogenic Human Coronaviruses in Relation to the COVID-19 Context.

TO THE EDITOR—Coronaviruses (CoV) comprise a large family of zoonotic RNA viruses. Among the 7 members known to infect humans, SARS-CoV-2, the causative agent of COVID-19, together with SARS-CoV and MERS-CoV, cause severe respiratory syndrome. The other 4 members, including NL63, HKU1, OC43, and 229E, are widely circulating in humans but predominantly cause mild respiratory tract illness [1]. Thus we call these 4 viruses low-pathogenic human CoVs (LPH-CoV). Two recent studies by Nickbakhsh et al and Monto et al in The Journal of Infectious Diseases have reported the prevalence of LPH-CoV as 4.0% in western Scotland and 8.3%–16.3% in Michigan, United States [2, 3]. Interestingly, both studies detected the highest frequency of infection in children younger than 5 years. This is the opposite to the COVID-19 pandemic where children are less commonly affected by SARS-CoV-2 [4]. These intriguing findings trigger important hypotheses on whether coinfection with LPH-CoV interferes with SARS-CoV-2 or exposure to LPH-CoV confers cross-protective immunity to some extent.

As COVID-19 is currently affecting the global population and research on LPH-CoV has been largely neglected in the past, we attempted to perform a systematic review and meta-analysis to map the global epidemiology of LPH-CoV. LPH-CoV–related studies from 1990 to March 2020 were systematically searched in Medline, Embase, Web of Science, Cochrane Central Register of Controlled Trials (CENTRAL), and Google scholar. Studies were included and data extracted only if they reported participants with symptoms of acute respiratory tract infections or influenza like illness. A 95% confidence interval (95% CI) was estimated using Wilson score method. Pooled prevalence (detection rate) was calculated using the DerSimonian-Laird random-effects model with Freeman-Tukey double arcsine transformation.

In total, 128 studies with 205 421 individuals were included, and an overall infection rate was estimated as 5.21% (95% CI, 4.62%–5.83%; I = 97%). The prevalence of LPH-CoV varied substantially among the reported 44 countries, from 0.73% (Philippines; 95% CI, 0.09%–1.84%) to 21.51% (Tunisia; 95% CI, 17.47%–25.83%) (Figure 1A and 1B). The number of available studies was very limited and many studies had small population sizes. This likely caused bias in prevalence estimations. Furthermore, similar to the studies of Nickbakhsh et al and Monto et al [2, 3], our included studies only detected LPH-CoV in individuals with respiratory illness or symptoms. This suggests that the prevalence rate of LPH-CoV in the general population could be even lower, raising the question of how large the impact could be on COVID-19.

Figure 1.

A, Global prevalence of LPH-CoV. The rate was determined as positive cases in tested populations with respiratory illness or symptoms. B, Forest plot of LPH-CoV prevalence among 44 countries. C, Monthly distribution of confirmed LPH-CoV cases. Abbreviations: CI, confidence interval; LPH-CoV, low-pathogenic human coronavirus.

Monto et al have nicely presented the seasonal distribution of the identified cases in Michigan according to the 4 LPH-CoV types [3]. We performed similar analyses by pooling 5 studies with relevant data, and all these studies were from countries in the northern hemisphere. We confirmed their findings that more cases were detected in the winter season (Figure 1C). However, we are cautious about the interpretation of these seasonal distribution data (Figure 1C) [3] because they only specified the identified cases and not the rate of infection, as the total number of tested cases in each month was not given. More importantly, whether SARS-CoV-2 will develop into a seasonal and/or endemic virus only time will tell [3].

In summary, we have comprehensively estimated the global prevalence of LPH-CoV among 44 countries and mapped their seasonal distribution. Our results further strengthen the epidemiological findings of Nickbakhsh et al and Monto et al, but also raise cautions about the interpretation of existing data. We agree that continued and enhanced monitoring of circulating HLP-CoV is necessary to understand how they may have an impact on the epidemiology and outcome of COVID-19 [5, 6].